Leaked: What’s in Obama’s trade deal
A recent draft of the Trans-Pacific Partnership free-trade deal would give U.S. pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in U.S. law.
POLITICO has obtained a draft copy of TPP’s intellectual property chapter as it stood on May 11, at the start of the latest negotiating round in Guam. While U.S. trade officials would not confirm the authenticity of the document, they downplayed its importance, emphasizing that the terms of the deal are likely to change significantly as the talks enter their final stages. Those terms are still secret, but the public will get to see them once the twelve TPP nations reach a final agreement and President Obama seeks congressional approval.
Still, the draft chapter will provide ammunition for critics who have warned that TPP’s protections for pharmaceutical companies could dump trillions of dollars of additional health care costs on patients, businesses and governments around the Pacific Rim. The highly technical 90-page document, cluttered with objections from other TPP nations, shows that U.S. negotiators have fought aggressively and, at least until Guam, successfully on behalf of Big Pharma.
The draft text includes provisions that could make it extremely tough for generics to challenge brand-name pharmaceuticals abroad. Those provisions could also help block copycats from selling cheaper versions of the expensive cutting-edge drugs known as “biologics” inside the U.S., restricting treatment for American patients while jacking up Medicare and Medicaid costs for American taxpayers.
“There’s very little distance between what Pharma wants and what the U.S. is demanding,” said Rohit Malpini, director of policy for Doctors Without Borders.
Throughout the TPP talks, the Obama administration has pledged to balance the goals of fostering innovation in the drug industry, which means allowing higher profits, and promoting wider access to valuable medicines, which means keeping prices down. U.S. Trade Representative Michael Froman has pointed out that pharmaceutical companies often have to invest hundreds of millions of dollars to get a new drug to market, which they would have little incentive to do without strong protections for the patented product. But Froman has also recognized the value of allowing much cheaper generic drugs to enter the market after those brand-name patents expire. In the U.S., generics now comprise more than five-sixths of all prescription drugs, but only about one-quarter of drug costs.
Advocates for the global poor, senior citizens, labor unions and consumers as well as the generics industry have accused the administration of abandoning that balance, pushing a pharmaceutical-company agenda at the expense of patients and taxpayers. One critic, hoping to illustrate the point and rally opposition to TPP in Congress, gave POLITICO the draft chapter, which was labeled “This Document Contains TPP CONFIDENTIAL Information” on every page.
U.S. officials said the key point to remember about trade deals is that no provision is ever final until the entire deal is final—and that major compromises tend to happen at the very end of the negotiations. They expect the real horse-trading to begin now that Obama has signed “fast-track” legislation requiring Congress to pass or reject TPP without amendments.
“The negotiations on intellectual property are complex and continually evolving,” said Trevor Kincaid, a spokesman for Froman. “On pharmaceutical products, we are working closely with stakeholders, Congress, and partner countries to develop an approach that aims to make affordable life-saving medicine more widely available while creating incentives for the development of new treatments and cures. Striking this important balance is at the heart of our work.”
The draft chapter covers software, music and other intellectual property issues as well, but its most controversial language involves the rights of drug companies. The text reveals disputes between the U.S. (often with support from Japan) and its TPP partners over a variety of issues—what patents can cover, when and how long they can be extended, how long pharmaceutical companies can keep their clinical data private, and much more. On every issue, the U.S. sided with drug companies in favor of stricter intellectual property protections.
Some of the most contentious provisions involve “patent linkage,” which would prevent regulators in TPP nations from approving generic drugs whenever there are any unresolved patent issues. The TPP draft would make this linkage mandatory, which could help drug companies fend off generics just by claiming an infringement. The Obama administration often describes TPP as the most progressive free-trade deal in history, citing its compliance with the tough labor and environment protections enshrined in the so-called “May 10 Agreement” of 2007, which set a framework for several trade deals at the time. But mandatory linkage seems to be a departure from the May 10 pharmaceutical provisions.
In an April 15 letter to Froman, Heather Bresch, the CEO of the generic drug company Mylan, warned that mandatory patent linkage would be “a recipe for indefinite evergreening of pharmaceutical monopolies,” leading to the automatic rejection of generic applications. The U.S. already has mandatory linkage, but most other TPP countries do not, and Bresch argued that U.S. law includes a number of safeguards and incentives for generic companies that have not made it into TPP.
“With all due respect, the USTR has…cherry-picked the single provision designed to block generic entry to the market,” Bresch wrote.
Generics are thriving in the U.S. despite linkage, saving Americans an estimated $239 billion on drugs in 2013. But the U.S. is the world’s largest market, and advocates fear that generic manufacturers may not take on the risk and expense of litigation in smaller markets if TPP tilts the playing field against them. One generics manufacturer, Hospira, reportedly testified at a TPP forum in Melbourne, Australia, that it would not launch generics outside the U.S. in markets with linkage.
The opponents are also worried about the treaty’s effect on the U.S. market, because its draft language would extend mandatory patent linkage to biologics, the next big thing in the pharmaceutical world. Biologics can cost hundreds of thousands of dollars a year for patients with illnesses like rheumatoid arthritis, hepatitis B and cancer, and the first knockoffs have not yet reached pharmacies. The critics say that extending linkage to biologics—which can have hundreds of patents—would help insulate them from competition forever.
“It would be a dramatic departure from U.S. law, and it would put a real crimp in the ability of less expensive drugs to get to market,” said K.J. Hertz, a lobbyist for AARP. “People are going to look at this very closely in Congress.”
Drug companies are already pushing for TPP to guarantee them 12 years of exclusivity for their data regarding biologics, although the draft text suggests the other TPP nations have not agreed. Jay Taylor, vice president of the Pharmaceutical Research and Manufacturers of America, said it’s crucial for TPP to protect the intellectual property that emerges from years of expensive research, so that drug companies can continue to develop new medicines for patients around the world.
“These innovations could be severely hindered if IP protections are scaled back,” Taylor said. “This is especially important in the area of biologic medicines, which could hold the key to unlocking treatments for diseases that have thwarted researchers for years.”
U.S. officials would not discuss the status of the TPP talks. But they suggested the May 10 Agreement did include a milder form of linkage, although it didn’t prevent regulators from approving generics mired in patent disputes. They also believe a 2009 U.S. law included a form of linkage for biologics, although again, that law's dispute resolution process for patent issues was not as prescriptive as the TPP draft. And they cautioned that any pre-Guam draft would not reflect recent negotiations over “transition periods” that would delay the stricter patent standards in developing countries like Vietnam.
In any case, Kincaid said U.S. negotiators are determined to strike a balance between innovation and access in the final product.
“While this is our touchstone, the negotiations are still very much in process, and the details of a final outcome cannot yet be forecasted,” he said.
But Malpani of Doctors Without Borders said U.S. negotiators have basically functioned as drug lobbyists. The TPP countries have 40 percent of global economic output, and the deal is widely seen as establishing new benchmarks for some of the most complex areas of global business. Malpani fears it could set a precedent that crushes the generic drug industry under a mountain of regulation and litigation.
“We consider this the worst-ever agreement in terms of access to medicine,” he said. “It would create higher drug prices around the world—and in the U.S., too.
Authors:
Michael Grunwaldmgrunwald@politico.comhttp://www.politico.com/agenda/story/2015/06/tpp-deal-leaked-pharma-000126
A recent draft of the Trans-Pacific Partnership free-trade deal would give U.S. pharmaceutical firms unprecedented protections against competition from cheaper generic drugs, possibly transcending the patent protections in U.S. law.
POLITICO has obtained a draft copy of TPP’s intellectual property chapter as it stood on May 11, at the start of the latest negotiating round in Guam. While U.S. trade officials would not confirm the authenticity of the document, they downplayed its importance, emphasizing that the terms of the deal are likely to change significantly as the talks enter their final stages. Those terms are still secret, but the public will get to see them once the twelve TPP nations reach a final agreement and President Obama seeks congressional approval.
Still, the draft chapter will provide ammunition for critics who have warned that TPP’s protections for pharmaceutical companies could dump trillions of dollars of additional health care costs on patients, businesses and governments around the Pacific Rim. The highly technical 90-page document, cluttered with objections from other TPP nations, shows that U.S. negotiators have fought aggressively and, at least until Guam, successfully on behalf of Big Pharma.
The draft text includes provisions that could make it extremely tough for generics to challenge brand-name pharmaceuticals abroad. Those provisions could also help block copycats from selling cheaper versions of the expensive cutting-edge drugs known as “biologics” inside the U.S., restricting treatment for American patients while jacking up Medicare and Medicaid costs for American taxpayers.
“There’s very little distance between what Pharma wants and what the U.S. is demanding,” said Rohit Malpini, director of policy for Doctors Without Borders.
Throughout the TPP talks, the Obama administration has pledged to balance the goals of fostering innovation in the drug industry, which means allowing higher profits, and promoting wider access to valuable medicines, which means keeping prices down. U.S. Trade Representative Michael Froman has pointed out that pharmaceutical companies often have to invest hundreds of millions of dollars to get a new drug to market, which they would have little incentive to do without strong protections for the patented product. But Froman has also recognized the value of allowing much cheaper generic drugs to enter the market after those brand-name patents expire. In the U.S., generics now comprise more than five-sixths of all prescription drugs, but only about one-quarter of drug costs.
Advocates for the global poor, senior citizens, labor unions and consumers as well as the generics industry have accused the administration of abandoning that balance, pushing a pharmaceutical-company agenda at the expense of patients and taxpayers. One critic, hoping to illustrate the point and rally opposition to TPP in Congress, gave POLITICO the draft chapter, which was labeled “This Document Contains TPP CONFIDENTIAL Information” on every page.
U.S. officials said the key point to remember about trade deals is that no provision is ever final until the entire deal is final—and that major compromises tend to happen at the very end of the negotiations. They expect the real horse-trading to begin now that Obama has signed “fast-track” legislation requiring Congress to pass or reject TPP without amendments.
“The negotiations on intellectual property are complex and continually evolving,” said Trevor Kincaid, a spokesman for Froman. “On pharmaceutical products, we are working closely with stakeholders, Congress, and partner countries to develop an approach that aims to make affordable life-saving medicine more widely available while creating incentives for the development of new treatments and cures. Striking this important balance is at the heart of our work.”
The draft chapter covers software, music and other intellectual property issues as well, but its most controversial language involves the rights of drug companies. The text reveals disputes between the U.S. (often with support from Japan) and its TPP partners over a variety of issues—what patents can cover, when and how long they can be extended, how long pharmaceutical companies can keep their clinical data private, and much more. On every issue, the U.S. sided with drug companies in favor of stricter intellectual property protections.
Some of the most contentious provisions involve “patent linkage,” which would prevent regulators in TPP nations from approving generic drugs whenever there are any unresolved patent issues. The TPP draft would make this linkage mandatory, which could help drug companies fend off generics just by claiming an infringement. The Obama administration often describes TPP as the most progressive free-trade deal in history, citing its compliance with the tough labor and environment protections enshrined in the so-called “May 10 Agreement” of 2007, which set a framework for several trade deals at the time. But mandatory linkage seems to be a departure from the May 10 pharmaceutical provisions.
In an April 15 letter to Froman, Heather Bresch, the CEO of the generic drug company Mylan, warned that mandatory patent linkage would be “a recipe for indefinite evergreening of pharmaceutical monopolies,” leading to the automatic rejection of generic applications. The U.S. already has mandatory linkage, but most other TPP countries do not, and Bresch argued that U.S. law includes a number of safeguards and incentives for generic companies that have not made it into TPP.
“With all due respect, the USTR has…cherry-picked the single provision designed to block generic entry to the market,” Bresch wrote.
Generics are thriving in the U.S. despite linkage, saving Americans an estimated $239 billion on drugs in 2013. But the U.S. is the world’s largest market, and advocates fear that generic manufacturers may not take on the risk and expense of litigation in smaller markets if TPP tilts the playing field against them. One generics manufacturer, Hospira, reportedly testified at a TPP forum in Melbourne, Australia, that it would not launch generics outside the U.S. in markets with linkage.
The opponents are also worried about the treaty’s effect on the U.S. market, because its draft language would extend mandatory patent linkage to biologics, the next big thing in the pharmaceutical world. Biologics can cost hundreds of thousands of dollars a year for patients with illnesses like rheumatoid arthritis, hepatitis B and cancer, and the first knockoffs have not yet reached pharmacies. The critics say that extending linkage to biologics—which can have hundreds of patents—would help insulate them from competition forever.
“It would be a dramatic departure from U.S. law, and it would put a real crimp in the ability of less expensive drugs to get to market,” said K.J. Hertz, a lobbyist for AARP. “People are going to look at this very closely in Congress.”
Drug companies are already pushing for TPP to guarantee them 12 years of exclusivity for their data regarding biologics, although the draft text suggests the other TPP nations have not agreed. Jay Taylor, vice president of the Pharmaceutical Research and Manufacturers of America, said it’s crucial for TPP to protect the intellectual property that emerges from years of expensive research, so that drug companies can continue to develop new medicines for patients around the world.
“These innovations could be severely hindered if IP protections are scaled back,” Taylor said. “This is especially important in the area of biologic medicines, which could hold the key to unlocking treatments for diseases that have thwarted researchers for years.”
U.S. officials would not discuss the status of the TPP talks. But they suggested the May 10 Agreement did include a milder form of linkage, although it didn’t prevent regulators from approving generics mired in patent disputes. They also believe a 2009 U.S. law included a form of linkage for biologics, although again, that law's dispute resolution process for patent issues was not as prescriptive as the TPP draft. And they cautioned that any pre-Guam draft would not reflect recent negotiations over “transition periods” that would delay the stricter patent standards in developing countries like Vietnam.
In any case, Kincaid said U.S. negotiators are determined to strike a balance between innovation and access in the final product.
“While this is our touchstone, the negotiations are still very much in process, and the details of a final outcome cannot yet be forecasted,” he said.
But Malpani of Doctors Without Borders said U.S. negotiators have basically functioned as drug lobbyists. The TPP countries have 40 percent of global economic output, and the deal is widely seen as establishing new benchmarks for some of the most complex areas of global business. Malpani fears it could set a precedent that crushes the generic drug industry under a mountain of regulation and litigation.
“We consider this the worst-ever agreement in terms of access to medicine,” he said. “It would create higher drug prices around the world—and in the U.S., too.
Authors:
Michael Grunwaldmgrunwald@politico.comhttp://www.politico.com/agenda/story/2015/06/tpp-deal-leaked-pharma-000126
Today at 5:28 pm by Rocky
» utube MM&C 4/16/24 IQD Update - Iraq Dinar - America - Activate - Massive Economic Deals -
Today at 5:24 pm by Rocky
» Al-Sudani urges the US corporation Honeywell to help finish the Basra refinery
Today at 2:48 pm by Rocky
» Al-Sudani Meets with Representatives of Western Media Outlets in Washington
Today at 2:46 pm by Rocky
» Chairman of the Investment Authority signs the United Nations Convention on International Mediation
Today at 2:44 pm by Rocky
» PM: We will sign a contract to establish the Al-Faw refinery with a Chinese company
Today at 2:42 pm by Rocky
» PM arrives in Houston as part of his visit to USA
Today at 2:41 pm by Rocky
» Militia Man & Crew 4/18/24 Bush signed it and all presidents implemented it. Iraq’s funds have been
Today at 1:46 pm by Rocky
» Association of Iraqi Private Banks: The suspension of some electronic payment services yesterday was
Today at 7:14 am by Rocky
» Iraq is close to launching the electronic signature
Today at 7:12 am by Rocky
» The Basra government discusses with an international oil company the implementation of social benefi
Today at 7:11 am by Rocky
» The Prime Minister confirms to an American company: Gas projects in Iraq are a priority for the gove
Today at 7:10 am by Rocky
» The Minister of Planning discusses with the World Bank mechanisms for scheduling external loans
Today at 7:09 am by Rocky
» Oil sets the twenty-seventh of this month as the date for opening contracts for the fifth complement
Today at 7:08 am by Rocky
» “Electronic begging”...professionalism and fabrication of stories” generates millions of dinars dail
Today at 7:05 am by Rocky
» Al-Sudani calls on the American company Hanwell to contribute to the completion of the Basra refiner
Today at 7:03 am by Rocky
» An American company expresses its willingness to establish LED lighting production lines in Iraq
Today at 7:02 am by Rocky
» Including Iraq.. Iran announces the possibility of exporting 300 megawatts of “renewable electricity
Today at 7:01 am by Rocky
» Political forces present two options to find an alternative to Al-Halbousi
Today at 6:58 am by Rocky
» Parliament is awaiting the arrival of the budget schedules and the government is studying higher spe
Today at 6:56 am by Rocky
» The International Monetary Fund adjusts its expectations for the development of the world’s economie
Today at 6:54 am by Rocky
» A representative talks about the difficulty of finalizing the file of “electing the Speaker of Parli
Today at 6:50 am by Rocky
» Work on preparing a law for diplomatic passports
Today at 6:49 am by Rocky
» A female representative accuses the Ministry of Immigration of corruption
Today at 6:47 am by Rocky
» Minister: Solving the Kurdistan salaries problem is the beginning of addressing other disputes betwe
Today at 6:45 am by Rocky
» About 270 million dollars were sold by the Central Bank of Iraq in the currency auction
Today at 6:42 am by Rocky
» The volume of trade exchange between Jordan and Iraq will exceed 800 million dinars in 2023
Today at 6:41 am by Rocky
» Iraq signs memorandums of understanding with American companies in the fields of electricity, oil an
Today at 5:31 am by Rocky
» The American company that manufactures the F16 expresses its readiness to implement the terms of con
Today at 5:30 am by Rocky
» The volume of expected Qatari investments for the Iraq Fund for Development exceeds $3.5 billion
Today at 5:29 am by Rocky
» Decrease in dollar prices in Baghdad and Erbil
Today at 5:27 am by Rocky
» The President of the Region brings together the Kurdish parties to resolve the election file
Today at 5:26 am by Rocky
» Al-Sudani receives in Washington the Chairman of JPMorgan
Today at 5:25 am by Rocky
» Transport is starting to transform its ports into smart ones
Today at 5:23 am by Rocky
» Sudanese reveals the volume of exchange with America
Today at 5:22 am by Rocky
» "Al-Eqtisad News" publishes the memorandums of understanding signed between the Iraqi delegation and
Today at 5:21 am by Rocky
» Al-Sudani urges an American company to contribute to establishing a chemical materials factory
Today at 5:20 am by Rocky
» Iraq stresses the importance of Lockheed Martin's commitment to opening military aircraft maintenanc
Today at 5:19 am by Rocky
» Iraq is on the verge of a “water disaster” by 2035
Today at 5:18 am by Rocky
» Great satisfaction and optimism with the results of Sudanese’s visit to Washington
Today at 5:16 am by Rocky
» Transport is beginning to adopt a plan to transform its ports into smart ones
Today at 5:15 am by Rocky
» Completed 8,000 loan transactions at the Housing Bank
Today at 5:14 am by Rocky
» Prime Minister: We plan to invest production capacities for export
Today at 5:12 am by Rocky
» Transformation and partnership...a new horizon in Iraqi-American relations
Today at 5:10 am by Rocky
» What is new in the economic dimension of the Washington visit?
Today at 5:09 am by Rocky
» Two letters to the future
Today at 5:08 am by Rocky
» National interests first
Today at 5:06 am by Rocky
» Iraqi-American rapprochement...a national necessity
Today at 5:05 am by Rocky
» Al-Sudani’s visit to Washington and the course of Iraqi-American relations
Today at 5:04 am by Rocky
» Sudanese carries security, economic and development files to Washington
Today at 5:03 am by Rocky
» Armament and military development... features of a sustainable partnership
Today at 5:02 am by Rocky
» Analysts: Sudanese's visit to Washington will achieve excellent results in the future
Today at 5:01 am by Rocky
» Iraqi-American relations...the legacy of the past and the aspirations of partnership
Today at 5:00 am by Rocky
» Sudanese and external necessities
Today at 4:59 am by Rocky
» The Strategic Framework Agreement... 7 important provisions
Today at 4:58 am by Rocky
» Joint statement of the Iraqi-American discussions
Today at 4:56 am by Rocky
» Supreme Coordinating Committee: Iraq's role is vital to the security and prosperity of the region
Today at 4:55 am by Rocky
» Towards an effective bilateral economic relationship between Baghdad and Washington
Today at 4:53 am by Rocky
» She saw it as a new, different chapter in Iraqi-American relations... Al-Sudani’s visit to Washingto
Today at 4:52 am by Rocky
» Al-Sudani’s visit to Washington.. Implications and results
Today at 4:51 am by Rocky
» Advisor to the Prime Minister: The relationship with America has moved to the stage of cooperation
Today at 4:50 am by Rocky
» Sudanese sponsors the signing ceremony of memorandums of understanding in America
Today at 4:47 am by Rocky
» Al-Sudani: The volume of exchange between Iraq and the United States does not exceed 10 billion doll
Today at 4:46 am by Rocky
» During Erdogan's visit on Monday, Iraq seeks to sign the "Water Protocol" with Türkiye
Today at 4:45 am by Rocky
» With the escalation of tension between Tehran and Tel Aviv...an expert reveals the secrets of Sudane
Today at 4:43 am by Rocky
» There are 150 draft laws on the parliament table waiting to be voted on... and the debates require c
Today at 4:42 am by Rocky
» Al-Sudani stresses the necessity of continuing the dialogue with the US Treasury, the Federal Reserv
Today at 4:41 am by Rocky
» Deputy: We reject the term sanctions, and Iraq is financially independent
Today at 4:38 am by Rocky
» Warnings of a “political impasse” after Barzani’s boycott of the elections... Al-Sadr raises questio
Today at 4:37 am by Rocky
» The head of the Kurdistan Regional Government’s representative office in Baghdad visits the external
Today at 4:36 am by Rocky
» Al-Sudani: There are no combat forces in Iraq to withdraw.. The Iraqi Prime Minister confirmed in Wa
Today at 4:34 am by Rocky
» Do the Iraqi political blocs really intend to hold the second early elections?
Today at 4:33 am by Rocky
» Baghdad is not aware of the factions’ participation in the attack on Israel, and Washington is revie
Today at 4:32 am by Rocky
» Progress: Al-Halbousi may return to the presidency of Parliament
Today at 4:30 am by Rocky
» Al-Sudani: Iraq has distinguished relations with Iran and America
Today at 4:30 am by Rocky
» Minister of Industry: Iraq is not a rich country and the electricity problem will not be solved even
Today at 4:29 am by Rocky
» A prospective law to employ prisoners and detainees... job and retirement opportunities similar to E
Today at 4:27 am by Rocky
» Sako in Baghdad.. Three possible scenarios for his return after the “withdrawal of the decree” crisi
Today at 4:26 am by Rocky
» Parliamentary Integrity reveals a move with the judiciary to recover TBI Bank’s funds
Today at 4:24 am by Rocky
» Iraq signs 18 memorandums of understanding with Washington
Today at 4:22 am by Rocky
» An Iraqi judicial delegation arrives in Syria to discuss terrorism files and document ISIS crimes
Today at 4:21 am by Rocky
» A plan to exploit new lands...the latest developments in the wheat, barley and rice season in Iraq
Today at 4:19 am by Rocky
» Al-Abadi accuses oil companies of causing 70% of the cancer rate in Basra
Today at 4:17 am by Rocky
» Justice announces the formation of a higher committee to resolve the state’s real estate file
Today at 4:16 am by Rocky
» Deputy: Iraq seeks to sign the “Water Protocol” with Türkiye
Today at 4:15 am by Rocky
» Al-Sudani stresses the importance of the American company Lockheed’s commitment to opening military
Today at 4:13 am by Rocky
» The team accompanying Sudanese in Washington: America will hand over to Iraq the antiquities that we
Today at 4:12 am by Rocky
» Al-Sudani sponsors the signing ceremony of memorandums of understanding with American companies
Yesterday at 3:38 pm by Rocky
» MM&C 4/17/24 Saleh: The budget tables are almost complete and will take into account urgent circu
Yesterday at 3:36 pm by Rocky
» Saleh: Private banks in Iraq are considering reorganizing themselves with another government structu
Yesterday at 3:33 pm by Rocky
» Al-Sudani: It is not possible to work in any development sector without reforming the banking sector
Yesterday at 3:32 pm by Rocky
» Minister of Oil: Kurdistan’s exports will soon resume, and the region must hand over its oil to SOMO
Yesterday at 3:30 pm by Rocky
» An economic expert identifies ways for Iraq to get out of oil rents... starting with $350 million
Yesterday at 3:29 pm by Rocky
» Parliamentary Oil: A proposal to establish Iraqi refineries in neighboring countries... and these ar
Yesterday at 3:28 pm by Rocky
» Al-Ardawi: The Sudanese government seeks to liberalize the Iraqi dinar and stabilize the economy
Yesterday at 3:27 pm by Rocky
» MM&C 4/17/24 Al-Sudani receives in Washington the Chairman of JPMorgan
Yesterday at 2:41 pm by Rocky
» MM&C 4/17/24 US Supports Iraq in joining WTO
Yesterday at 2:36 pm by Rocky
» US Supports Iraq in joining WTO
Yesterday at 10:17 am by Rocky
» utube 4/14/24 MM&C Iraqi Dinar - Iraq Prime Minister in Washington - Coming to
Yesterday at 8:58 am by Rocky